OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer

20257 citationsJournal Articlehybrid Open Access

Authors

Premal H. Thaker · Washington University in St. Louis

Debra L. Richardson · Oklahoma State University Oklahoma City

Andrea R. Hagemann · Washington University in St. Louis

Robert W. Holloway · Florida Hospital Cancer Institute

Mark S. Reed · West Cancer Center

Melanie K Bergman · Providence Sacred Heart Medical Center

Bhavana Pothuri

Abstract

The addition of IMNN-001 to N/ACT shows a promising numerical 13-mo benefit on survival with an acceptable safety profile in patients with newly-diagnosed advanced EOC.

Topics & Keywords

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy Virus-based gene therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gynecologic Oncology

Volume 197, pp. 182-191

DOI: 10.1016/j.ygyno.2025.04.578

Field-Weighted Citation Impact: 12.73